ENSC

S-3 - Ensysce Biosciences, Inc. (0001716947) (Filer)

8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~~ Company Launches Formal Review of Strategic Alternatives ~ SAN DIEGO, CA / ACCESS Newswire / May 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today reported financial and operational results for the first quarter ended March 31, 2026."The first quarter of 2026 delivered meaningful operational and clinical momentum across our pipeline, un

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce's MPAR® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, announced that CEO, Dr. Lynn Kirkpatrick, presented as an invited speaker and was featured on a panel at the first Pain Therapeutics Summit Europe held in Amsterdam May 7-8, 2026.This meeting gathered experts from around the world to discuss latest advancements in analgesic care, including novel therapeutic candidates in development. Dr. Kirkpatrick's presen

S-8 - Ensysce Biosciences, Inc. (0001716947) (Filer)

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced Investigational Review Board (IRB) approval to initiate Part 3 of the PF614-MPAR-102 clinical study, marking the final stage in this study evaluating its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology.PF614-MPAR, which received Breakthrough Therapy designation from the U.S. FDA following the PF614-MPAR-101 study

EFFECT - Ensysce Biosciences, Inc. (0001716947) (Filer)

S-3 - Ensysce Biosciences, Inc. (0001716947) (Filer)

8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a second convertible preferred stock financing of $2 million under prior commitment in November 2025 of up to $20 million funding available over 24 months.The capital will maintain Ensysce's flagship analgesic programs, while supporting general corporate initiatives. The current $2 million tranche includes a fixed conversion price of $0.55

8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

10-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025."2025 was a year of meaningful progress for Ensysce, marked by significant clinical advancement, productive regulatory engagement, and continued strengthening of our intellectual property portfolio," said Dr.

8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 4, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the successful initiation of its live "Ask Me Anything" (AMA) series on March 4, 2024.The event reinforced the Company's commitment to transparency, accessibility, and open dialogue with its community. A replay of the AMA series is available on the Compa

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the publication of the first clinical manuscript describing its MPAR® (Multi-Pill Abuse Resistance) overdose protection technology.The paper, titled "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," appe

8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

DENVER, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation, positioning themselves for potential continued follow-through. From biomaterials scale-up to enterprise AI deployment and disciplined capital allocation, these names are building narratives that extend beyond a single news cycle. Kraig Biocraft Laboratories: From Strategy to Scale Activity has accelerated at Kraig Biocraft Laboratories (OTCQB:KBLB) following confirmation that its 2026 production plan has officially transitioned from roadmap to execution. The company has moved bio

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced its Board of Directors has initiated a formal review of a broad range of strategic alternatives intended to enhance shareholder value and support the continued advancement of the Company's proprietary technologies.Potential strategic alternatives may include, among other t

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced that members of its executive management team including Dr. Lynn Kirkpatrick, Dr. William Schmidt and Mr. Geoff Birkett have been invited to participate in upcoming scientific and industry events focused on next-generation pain therapeutics, substance use disorder res

~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced it has enrolled 50% of subjects targeted for interim review in its pivotal Phase 3 clinical trial of PF614, the Company's next-generation opioid candidate engineered to deliver powerful pain relief with built-in abuse protection..Enrollment began in late December 2025 and is progressing rapidly across three U.S. clinical sites: CenExel JBR (Salt Lake City,

~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the Brazilian Patent Office for the issuance of a patent* covering additional opioid families, utilizing the Company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.The newly allowed patent includes both comp

8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)